ARTICLE | Company News
OGS submits Vevesca NDA
August 21, 2001 7:00 AM UTC
Oxford GlycoSciences (LSE:OGS; OGSI) completed the rolling submission of its NDA for Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor ( OGT 918) to treat Type I Gaucher disease. The ...